Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

Posted by on Jan 11th, 2025

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a report released on Thursday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 7.2 %

NYSE BTX opened at $0.30 on Thursday. The company has a 50-day moving average price of $0.49 and a two-hundred day moving average price of $1.16. The stock has a market cap of $17.65 million, a price-to-earnings ratio of -0.13 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52 week low of $0.17 and a 52 week high of $10.10.

About Brooklyn ImmunoTherapeutics

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

Further Reading

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.